Preclinical Characterization of a Novel SSEA-4-Targeting Antibody-Drug Conjugate, OBI-998

I-J Chen1, Chun-Chung Wang1, Chi-Sheng Shih1, Chung-Chen Su1, Chi-Huan Lin1, Hui-Wen Chang1, Ping-Tau Chi1, Yueh-Chin Wu1, Ming-Tain Lai1, Wei-Chien Tang1, Hsin-Yi Tung1, and Ren-Yu Hsu1

1OBI Pharma, Inc., Taipei, Taiwan

BACKGROUND

- SSEA-4 is an antigen present in multiple cancers and can be a therapeutic target.
- OBI-998 is a novel ADC targeting SSEA-4.

OBJECTIVE

We investigated the potential of OBI-998 as a therapeutic agent for cancer treatment.

RESULTS

- OBI-998 is a novel ADC targeting SSEA-4.
- It has demonstrated antitumor efficacy in multiple cancer models.
- Pharmacokinetic and tissue distribution studies were conducted.

CONCLUSIONS

- OBI-998 has shown promising results in preclinical studies.
- It demonstrates antitumor activity in multiple cancer models.
- Further development is warranted for clinical trials.

REFERENCES